Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy

Michael Gough, Marka Crittenden, Uma Thanarajasingam, Luis Sanchez-Perez, Jill Thompson, Dragan Jevremovic, Richard Vile

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Strategies that generate tumor Ag-specific effector cells do not necessarily cure established tumors. We hypothesized that the relative efficiency with which tumor-specific effector cells reach the tumor is critical for therapy. We demonstrate in this study that activated T cells respond to the chemokine CCL3, both in vitro and in vivo, and we further demonstrate that expression of CCL3 within tumors increases the effector T cell infiltrate in those tumors. Importantly, we show that adenoviral gene transfer to cause expression of CCL3 within B16ova tumors in vivo increases the efficacy of adoptive transfer of tumor-specific effector OT1 T cells. We additionally demonstrate that such therapies result in endogenous immune responses to tumor Ags that are capable of protecting animals against subsequent tumor challenge. Strategies that modify the "visibility" of tumors have the potential to significantly enhance the efficacy of both vaccine and adoptive transfer therapies currently in development.

Original languageEnglish (US)
Pages (from-to)5766-5773
Number of pages8
JournalJournal of Immunology
Issue number9
StatePublished - May 1 2005

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy'. Together they form a unique fingerprint.

Cite this